STCOSD
ENTA icon

Sageworth Trust Company of South Dakota’s Enanta Pharmaceuticals ENTA Stock Holding History

Sageworth Trust Company of South Dakota’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed – – 362
2022
Q2 		$0 Hold
10
– – ﹤0.01% 613
2022
Q1 		$1K Sell
10
-54
-84% -$3.51K ﹤0.01% 501
2021
Q4 		$5K Buy
+64
New +$5.02K 0.01% 510

Other funds holding ENTA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Sageworth Trust Company of South Dakota's ENTA Position: Q3 2022 in Review

Sageworth Trust Company of South Dakota sold out of Enanta Pharmaceuticals (ENTA) in Q3 2022, closing a stake of 10 shares.

Sageworth Trust Company of South Dakota first reported a position in ENTA in Q4 2021 and held it in 3 quarters. The position peaked at $5K in Q4 2021. 160 funds tracked by Wall St. Rank hold ENTA as of Q3 2022.

  • Sageworth Trust Company of South Dakota reported no remaining Enanta Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Sageworth Trust Company of South Dakota sold 10 Enanta Pharmaceuticals shares in Q3 2022.
  • Sageworth Trust Company of South Dakota first reported a position in Enanta Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Sageworth Trust Company of South Dakota's Enanta Pharmaceuticals position peaked at $5K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2022.

Based on Sageworth Trust Company of South Dakota's 13F filing for Q3 2022, filed 2 Nov 2022.